| [1] |
Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J].J Clin Oncol, 2002, 20(22):4420–4427.
|
| [2] |
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26):2609–2617.
|
| [3] |
Jagannath S, Barlogie B,Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma[J]. Br J Hematol, 2004, 127(2):165–172.
|
| [4] |
Richardson PG, Sonneveld P,Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24):2487–2498.
|
| [5] |
Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial[J]. Blood, 2007, 110(10):3557–3560.
|
| [6] |
Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma[J]. Br J Haematol, 2009, 144(6):887–894.
|
| [7] |
Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma[J]. J Clin Oncol, 2008, 26(29):4777–4783.
|
| [8] |
San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma[J]. J Clin Oncol, 2013, 31(4):448–455.
|
| [9] |
Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients[J]. Blood, 2009, 114(27):5436–5443.
|
| [10] |
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2015, 372(2):142–152.
|
| [11] |
Richardson PG, Baz R,Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients[J]. Blood, 2014, 124(7):1038–1046.
|
| [12] |
Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis[J]. Leukemia, 2011, 25(4):689–696.
|
| [13] |
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366(19):1770–1781.
|
| [14] |
San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2013, 14(11):1055–1066.
|
| [15] |
Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial[J]. Br J Haematol, 2008, 143(2):191–200.
|
| [16] |
Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma[J].Br J Haematol, 2012, 156(4):552–555.
|
| [17] |
Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease[J]. Br J Haematol, 2011, 155(5):632–634.
|
| [18] |
San-Miguel JF, Hungria VT,Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1195–1206.
|